Rabbit ATLG and thymoglobulin in haploidentical hematopoietic cell transplantation product specific evidence and unresolved dosing with PTCy

Rabbit anti-T-lymphocyte globulin (ATLG; Grafalon) and rabbit anti-thymocyte globulin (ATG; Thymoglobulin) are noninterchangeable polyclonal preparations used within haploidentical hematopoietic cell transplantation (haplo-HCT) platforms. Their immunogens, antibody repertoires and nominal dose scales differ, but direct comparative clinical evidence is sparse. This narrative review examines product-specific evidence, active-antibody exposure and the unresolved dosing of serotherapy combined with post-transplant cyclophosphamide (PTCy). The available propensity-matched haploidentical comparison used Thymoglobulin 6 mg/kg and ATLG 10 mg/kg; the latter was substantially below ATLG totals commonly used even in matched-donor transplantation. Its infection and chronic graft-versus-host disease findings therefore cannot establish intrinsic product differences. PTCy-based and serotherapy-based platforms coexist, including outside Western centers, and neither the optimal rabbit-globulin dose nor the optimal PTCy dose in combined regimens is established. Recipient absolute lymphocyte count (ALC), infusion timing and graft cellularity modify exposure. ATLG-specific ALC studies support this association, but prospectively validated ATLG ALC-based dosing models remain needed. Product, conditioning, graft source, PTCy, mycophenolate mofetil and other immunosuppression should be evaluated as one protocol. Clinical use should follow product-specific, locally validated regimens while trials define exposure targets and the net benefit of combination prophylaxis.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Medicine
Published
2026-11-16
DOI
https://doi.org/10.1007/s10238-026-02395-x
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rabbit ATLG and thymoglobulin in haploidentical hematopoietic cell transplantation product specific evidence and unresolved dosing with PTCy

Yi Xiao, Yu Wang
2 links
Clinical and Experimental Medicine
Hematopoietic Stem Cell Transplantation
article

Rabbit ATLG and thymoglobulin in haploidentical hematopoietic cell transplantation product specific evidence and unresolved dosing with PTCy

Yi Xiao, Yu Wang
article en

Abstract

Rabbit anti-T-lymphocyte globulin (ATLG; Grafalon) and rabbit anti-thymocyte globulin (ATG; Thymoglobulin) are noninterchangeable polyclonal preparations used within haploidentical hematopoietic cell transplantation (haplo-HCT) platforms. Their immunogens, antibody repertoires and nominal dose scales differ, but direct comparative clinical evidence is sparse. This narrative review examines product-specific evidence, active-antibody exposure and the unresolved dosing of serotherapy combined with post-transplant cyclophosphamide (PTCy). The available propensity-matched haploidentical comparison used Thymoglobulin 6 mg/kg and ATLG 10 mg/kg; the latter was substantially below ATLG totals commonly used even in matched-donor transplantation. Its infection and chronic graft-versus-host disease findings therefore cannot establish intrinsic product differences. PTCy-based and serotherapy-based platforms coexist, including outside Western centers, and neither the optimal rabbit-globulin dose nor the optimal PTCy dose in combined regimens is established. Recipient absolute lymphocyte count (ALC), infusion timing and graft cellularity modify exposure. ATLG-specific ALC studies support this association, but prospectively validated ATLG ALC-based dosing models remain needed. Product, conditioning, graft source, PTCy, mycophenolate mofetil and other immunosuppression should be evaluated as one protocol. Clinical use should follow product-specific, locally validated regimens while trials define exposure targets and the net benefit of combination prophylaxis.

Clinical and Experimental Medicine
Tongji Hospital (CN), Huazhong University of Science and Technology (CN)
National Natural Science Foundation of China
Good health and well-being
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon